RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients

Blog Article

BackgroundAdjuvant chemotherapy is a major adjuvant treatment modality for hormonal receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients derive practical benefits.How to balance its potential benefits and risks becomes a challenging clinical problem.The purpose of this study was to assess whether RecurIndex assay could serve as an aid for adjuvant chemotherapy decisions in Chinese patients with HR-positive HER2-negative early breast cancer.MethodsThe tissue samples of pT1-2N0 HR-positive bottoms HER2-negative breast cancer from multiple centers were detected using RecurIndex assay, based on which the patients were assigned into low- and high-risk groups.

The survival outcomes of low- and high-risk patients including those with and without adjuvant chemotherapy were compared, and the risk factors for recurrence and metastasis were identified.ResultsTotally 445 patients were eligible for analysis.By contrast to high-risk patients, low-risk patients represented better 7-year recurrence-free survival (RFS), distant recurrence-free survival (DRFS) and local recurrence-free survival (LRFS) rates.For low-risk patients, no significant differences were shown between those with and without adjuvant chemotherapy in 7-year RFS, DRFS and LRFS rates.

These differences were also inapparent between HOT CHOC ORIGINAL DARK high-risk patients with and without adjuvant chemotherapy.The multivariate model revealed high-risk patients had a significantly elevated risk of recurrence and metastasis than those at low risk.ConclusionHR-positive HER2-negative early breast cancer patients at low risk stratified by RecurIndex assay might be exempt from adjuvant chemotherapy.Whether adjuvant chemotherapy may derive survival benefits for high-risk patients still needs larger cohorts to verify.